Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells

BACKGROUND: Pancreatic cancer remains the deadliest of all cancers, with a mortality rate of 91%. Gemcitabine is considered the gold chemotherapeutic standard, but only marginally improves life-span due to its chemical instability and low cell penetrance. A new paradigm to improve Gemcitabine’s ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Papa, Anne-Laure, Basu, Sudipta, Sengupta, Poulomi, Banerjee, Deboshri, Sengupta, Shiladitya, Harfouche, Rania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543259/
https://www.ncbi.nlm.nih.gov/pubmed/22998550
http://dx.doi.org/10.1186/1471-2407-12-419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543259/
https://www.ncbi.nlm.nih.gov/pubmed/22998550
http://dx.doi.org/10.1186/1471-2407-12-419

Ejemplares similares